1. Systematic evaluation of Liuweiwuling Tablets for treatment of liver fibrosis resulting from chronic hepatitis B
Chinese Traditional and Herbal Drugs 2016;47(17):3133-3142
Objective: To systematicly evaluate the efficacy and safety of Liuweiwuling Tablets combined with nucleotide drugs for the treatment of liver fibrosis resulting from chronic hepatitis B. Methods: Major databases (such as Pubmed, Embase, Cochrane Library (Issue 9, 2015), Chinese Biomedical Database (CBM), China National Knowledge Infrastructure (CNKI), VIP, and WanFang Data were searched from their inception to September 9, 2015 to collect comprehensively randomized controlled trials (RCT) of Liuweiwuling Tablets combined with nucleotide drugs on the treatment of liver fibrosis resulting from chronic hepatitis B. After two reviewers separately screened literature according to the inclusion and exclusion criteria, extracted data, and assessed the methodological quality of the included studies, data were analyzed with RevMan 5.3 software. Results: The total seven RCTs were included. Among all 1 021 patients involved, 529 cases were in the treatment group, while the other 492 cases were in the control group. The findings showed that compared with using nucleotide drugs alone for antiviral treatment, Liuweiwuling Tablets combined with nucleotide drugs were more efficiently in downregulating serum liver fibrosis index HA [SMD = -1.26, 95% CI (-1.92, -0.59), P = 0.000 2], LN [SMD = -1.55, 95% CI (-2.27, -0.83), P < 0.000 1], PC-III [SMD = -1.39, 95% CI (-2.21, -0.58), P = 0.000 8], IV-C [SMD = -1.49, 95% CI (-2.25, -0.72), P = 0.0001]; improved the liver function ALT [SMD = -1.17, 95% CI (-1.41, -0.94), P < 0.000 01], AST [SMD = -1.25, 95% CI (-1.54, -0.96), P < 0.000 01], TBIL [SMD = -0.87, 95% CI (-1.21, -0.53), P < 0.000 01]; increased total clinical effective rate [OR = 4.59, 95% CI (2.05, 10.25), P = 0.000 2]. While no advantage was found in reducing the incidences of HBV DNA overcast [OR = 1.51, 95% CI (0.96, 2.39), P = 0.08]; No significant adverse reactions were reported. Conclusion: Liuweiwuling Tablets combined with nucleotide drugs could be effective in improving liver function, controlling liver fibrosis, and increasing total clinical effective rate while its antiviral efficacy approximate with using the nucleotide drugs alone, less adverse reaction, and better tolerability; Although in recent years, the quantity and quality of RCTs research have a rising trend year by year, but still need to be from the clinical design of scientific, the standardization of the report, and many other links to improve research level.
2.Inhibitory Effects and Mechanism of Lutein on Nasopharyngeal Carcinoma C666-1 Cells
Min SHEN ; Hui LIU ; Lijia WAN
China Pharmacy 2016;27(1):53-55
OBJECTIVE:To study the inhibitory effects and mechanism of lutein on nasopharyngeal carcinoma C666-1 cells. METHODS:C666-1 cells were stimulated by lutein at different concentrations [0(blank control),20,40,80,160 mg/L] for dif-ferent time(0,12,24,48 h). The proliferation rate of cells was determined by CCK-8 assay,and apoptotic rate of cells was deter-mined by TUNEL method;Western blot was adopted to determine the phosphorylation of S6K and S6 proteins of AMPK and mTOR pathway. RESULTS:Compared with blank control group,proliferation rate of C666-1 cells was significantly reduced after treated with lutein(80,160 mg/L)for 48 h and lutein(160 mg/L)for 12,24,48 h(P<0.05). After treated with lutein(80,160 mg/L)for 48 h and lutein(160 mg/L)for 24,48 h,cell apoptosis was significantly increased(P<0.05). Lutein(80,160 mg/L) could promote intracellular AMPK phosphorylation,and inhibits mTOR pathway S6K,S6 protein phosphorylation after 48 h treat-ment (P<0.05). CONCLUSIONS:Lutein can inhibit nasopharyngeal carcinoma C666-1 cell proliferation and induce nasopharyn-geal carcinoma cell apoptosis and inhibit S6K,S6 protein phosphorylation through promoting AMPK phosphorylation.
3.Studies on the dynamic changes in brain natriuretic peptide of patients with heart failure treated with metoprolol (a report of 65 cases)
Hui ZHANG ; Xiangrong GONG ; Min LIU
Medical Journal of Chinese People's Liberation Army 1983;0(05):-
Objective To investigate the dynamic changes in brain natriuretic peptide (BNP) and the outcome of patients with chronic congestive heart failure (CHF) after the treatment with metoprolol. Methods Sixty-five patients with CHF were admitted to the Forth Affiliated Hospital of Zhengzhou University during April 2004 to April 2007, and they fulfilled the diagnostic criteria of chronic CHF issued by New York Heart Association (NYHA). Of all the patients the left ventricular end-diastolic dimension (LVEDD) ≥65mm. All the patients were randomly assigned into metoprolol group (34 cases) and control group (31 cases), and received conventional therapies [rest, reduced sodium intake, administration of digitalis, diuretic, angiotensin-converting enzyme inhibitor (ACEI) and aldosterone antagonists, etc.]. The patients in metoprolol group were given metoprolol (6.25mg as initiative dose and dose was increased according to illness). NYHA functional classitication, cardiothoracic ratio on chest X-ray film, cardiac output (CO), cardiac index (CI), left ventricular ejection fraction (EF) and LVEDD in echocardiogram were observed, and the plasma BNP level was determined with an immunoradiometric assay (IRMA). Results After 5 months of treatment, the clinical symptoms of patients were improved obviously and p1asma BNP level was significantly lowered in both groups, while p1asma BNP level was significantly lower in metoprolol group compared with control group (200.6?12.1 vs 120.7?14.1, P
4.Immediate implant placement in periodontally infected sitescombined with concentrate growth factors:a clinical study
Acta Universitatis Medicinalis Anhui 2017;52(8):1255-1257,1260
To investigate whether the use of concentrate growth factors have a favorable impact on clinical outcome of immediate implant in periodontally infected sites.48 patients with 51 teeth with periodontitis and periapical periodontitis accepted immediate implantation in the maxillary esthetic zone.25 implants(test group) were placed simultaneously with guided bone regeneration (GBR) using CGF combined with Bio-oss, other 26 implants(control group) were treated with Bio-oss alone.The facial bone thickness at 0, 4 and 8mm apical to the implant platform were measured immediately after, 3 months after and 6 months after surgery;pain visual analogue scale (VAS) was used to assess the degreeof pain in the patient within 1 week after surgery.3 months after surgery,the change of horizontal resorption in labial was less in test group(P<0.05).In the first three days postsurgery, the test group reported significantly less pain with respect to the control group(P<0.05).The application of CGF produced beneficial impacts on clinical outcome of immediate implant in periodontally infected sites.
5.Correlation between plasma N-terminal pro-brain natriuretic peptide and haemodynamics in patients with chronic thromboembolic pulmonary hypertension
Hui LONG ; Yuanhua YANG ; Min LIU
Chinese Journal of Postgraduates of Medicine 2015;38(2):87-89
Objective To investigate the correlation between plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) and haemodynamics evaluated by right-heart catheterization in patients with chronic thromboembolic pulmonary hypertension (CTEPH).Methods Fifty-three patients with CTEPH were retrospectively reviewed.All patients underwent right-heart catheterization to detect haemodynamics.The level of plasma NT-proBNP was measured by electrochemical luminescence.The indexes were analyzed.Results Pulmonary artery systolic pressure was (84.9 ± 21.6) mmHg (1 mmHg =0.133 kPa).Pulmonary artery diastolic pressure was (31.1 ± 9.7) mmHg.Pulmonary artery pressure was (49.3 ± 13.4) mmHg.Pulmonary vascular resistance was (1 047.4 ± 86.1) dyn ·s/cm5.Pulmonary capillary wedge pressure was (8.16 ± 3.02) mmHg.Right cardiac output was (3.36 ± 1.42) ml.Right cardiac work was (1.97 ± 0.95) kg·m.The level of plasma NT-proBNP in CTEPH was (2 301.5 ± 1 787.3) ng/L.The level of plasma NT-proBNP in CTEPH had positive correlation with pulmonary vascular resistance (r =0.429,P =0.02),and had negative correlation with right cardiac output (r =-0.583,P< 0.01) and right cardiac work (r =-0.521,P < 0.01).The level of plasma NT-proBNP in CTEPH had no correlation with pulmonary artery systolic pressure,pulmonary artery diastolic pressure,pulmonary artery pressure,pulmonary capillary wedge pressure (P > 0.05).Conclusion The level of plasma NT-proBNP can be used as a better predictor for evaluating pulmonary vascular resistance and right cardiac function in CTEPH.
10.Effect of Zhuyun Capsule on Expression of Ovarian Cytokine of Polycystic Ovary Syndrome Rats
Yan-Qiao LIU ; Hui-Min DANG ; Run-Xia LIU ;
Journal of Traditional Chinese Medicine 1993;0(05):-
Objective To observe the effect of Zhuyun Capsule(Pregnant-promoting Capsule)on serum sex hormone and expres- sion of ovarian cytokine of polycystic ovary syndrome(PCOS)rats.Methods Progestogen plus human chorionic gonadotrophin (HCG)was adopted to make PCOS rat models.Totally 40 SD rats were randomized into control group,PCOS model group,Zhuyun Capsule group,and clomiphene citrate group with 10 in each.Radioimmune assay(RIA)was used to measure the sex hormone and immunohistochemical test was done to measure the expression of tumor necrosis factor-?(TNF-?)of ovarian tissue,insulin-like growth factors-1(IGF-1),and leukemia inhibitory factor(LIF)to analyze the relations among these factors.Results Zhuyun Capsule could reduce greatly serum testosterone(T)and luteinizing hormone(LH),decrease expression of TNF-?and IGF-1,but increase expres- sion of LIF.Conclusion Zhuyun Capsule could regulate endocrine function and expression of ovarian cytokine to improve gonad func- tions of PCOS rats and to promote the maturation of follicle and ovulation.